Immunologic Effectiveness of Maraviroc- and Raltegravir-Containing Regimens (R+M+) versus Raltegravir-Based Regimens That Do Not Include Maraviroc (R+M−)

Objective: To compare the immunologic effectiveness of raltegravir–maraviroc (R+M+)-based regimens with raltegravir-based regimens that do not include maraviroc (R+M−) in treatment-experienced patients in clinical practice. Methods: We conducted a retrospective study of treatment-experienced HIV-inf...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the International Association of Physicians in AIDS Care 2012-06, Vol.11 (3), p.192-197
Main Authors: Antoniou, Tony, Smith, Graham, Su, DeSheng, Raboud, Janet M., Lee, Derek, Kovacs, Colin, Brunetta, Jason, Fletcher, David, Crouzat, Fred, Loutfy, Mona
Format: Article
Language:English
Subjects:
Anti-HIV Agents - immunology
Anti-HIV Agents - therapeutic use
Antiretroviral drugs
Antiretroviral Therapy, Highly Active
CD4 Lymphocyte Count
Cyclohexanes - immunology
Cyclohexanes - therapeutic use
Female
HIV Infections - drug therapy
HIV Infections - immunology
HIV Infections - virology
Human immunodeficiency virus
Humans
Male
Middle Aged
Patients
Pyrrolidinones - immunology
Pyrrolidinones - therapeutic use
Raltegravir Potassium
Retrospective Studies
Triazoles - immunology
Triazoles - therapeutic use
Viral Load
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: To compare the immunologic effectiveness of raltegravir–maraviroc (R+M+)-based regimens with raltegravir-based regimens that do not include maraviroc (R+M−) in treatment-experienced patients in clinical practice. Methods: We conducted a retrospective study of treatment-experienced HIV-infected adults receiving either R+M+- or R+M−-based therapy. Longitudinal CD4 counts were analyzed using a linear mixed model. Results: One hundred and fifty-six patients were included in the analysis, of whom 32 were receiving R+M+ and 124 R+M−. Mean baseline CD4 counts in patients on R+M+ and R+M− were 463.8 and 442.3 cells/mm3, respectively (P = .67). In multivariable mixed models, a baseline viral load ≥50 copies/mL was significantly associated with CD4 change during follow-up (P < .0001). No difference between R+M+ and R+M− was observed during follow-up (P = .81). Conclusion: CD4 cell recovery was similar among patients receiving either R+M+- or R+M−-based therapy during a 24-month period of follow-up.
ISSN:1545-1097
2325-9574
1557-0886
2325-9582
DOI:10.1177/1545109711424967